首页> 美国卫生研究院文献>Diabetes Care >Efficacy and Safety of Exenatide Once Weekly Versus Metformin Pioglitazone and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

【2h】

Efficacy and Safety of Exenatide Once Weekly Versus Metformin Pioglitazone and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

机译：艾塞那肽每周一次与二甲双胍吡格列酮和西格列汀对单药治疗的初治2型糖尿病患者的疗效和安全性（DURATION-4）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

OBJECTIVETo test the safety and efficacy of exenatide once weekly (EQW) compared with metformin (MET), pioglitazone (PIO), and sitagliptin (SITA) over 26 weeks, in suboptimally treated (diet and exercise) drug-naive patients with type 2 diabetes.

机译：目的在26周内，对未经药物治疗的2型糖尿病初治患者进行艾塞那肽（EQW）与二甲双胍（MET），吡格列酮（PIO）和西他列汀（SITA）相比每周一次的安全性和有效性测试。

著录项

期刊名称 Diabetes Care
作者
David Russell-Jones; Robert M. Cuddihy; Markolf Hanefeld; Ajay Kumar; Jose G. González; Melanie Chan; Anne M. Wolka; Marilyn K. Boardman;
展开▼
作者单位

展开▼
年(卷),期 2012(35),2
年度 2012
页码 252–258
总页数 7
原文格式 PDF
正文语种
中图分类护理学;
关键词

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. [J] . Russell Jones D, Cuddihy RM, Hanefeld M, Diabetes care . 2012,第2期

机译：埃塞那肽每周两次与二甲双胍，吡格列酮和西他列汀作为单药治疗未使用过药物的2型糖尿病患者的疗效和安全性（DURATION-4）：一项为期26周的双盲研究。
2. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. [J] . Russell Jones D, Cuddihy RM, Hanefeld M, Diabetes care . 2012,第2期

机译：艾塞纳西亚肽的功效和安全性与二甲双胍，吡格列酮和SitaGliptin用作2型糖尿病患者的单药治疗（持续时间4）：26周的双盲研究。
3. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. [J] . Russell Jones D, Cuddihy RM, Hanefeld M, Diabetes care . 2012,第2期

机译：艾塞纳西亚肽的功效和安全性与二甲双胍，吡格列酮和SitaGliptin用作2型糖尿病患者的单药治疗（持续时间4）：26周的双盲研究。
4. Efficacy and Safety of Right Versus Left Transradial Approach for Invasive Coronary Procedures in Octogenarian Patients [C] . Gomez-Blazquez I., Fernez-Barbeira S., Jimenez-Diaz V.A., International Congress on Coronary Artery Disease. . 2013

机译：术语术语患者侵袭性冠状动脉术治疗右颅跨度方法的疗效和安全性
5. A 4-month randomized controlled clinical trial of adjuvant Exenatide or Pramlintide versus insulin alone in pediatric type 1 diabetes mellitus: Effect on glycemic control. [D] . Withycombe, Sarah Elizabeth. 2010

机译：儿科1型糖尿病患者中艾塞那肽或普兰林肽与单独使用胰岛素的4个月随机对照临床试验：对血糖控制的影响。
6. Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial [O] . Serge A. Jabbour, Juan P. Frías, Elise Hardy, 2018

机译：二甲双胍单药治疗不能完全控制的2型糖尿病患者艾塞那肽每周一次加艾达那列或每日一次与艾塞那肽或达格列净相比的安全性和有效性：DURATION-8随机对照试验52周的结果
7. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. [O] . Russell-Jones, D, Cuddihy, RM, Hanefeld, M, 2012

机译：艾塞那肽每周两次与二甲双胍，吡格列酮和西他列汀作为单药治疗未使用过药物的2型糖尿病患者的疗效和安全性（DURATION-4）：一项为期26周的双盲研究。

Efficacy and Safety of Exenatide Once Weekly Versus Metformin Pioglitazone and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

摘要

著录项

相似文献

相关主题

期刊订阅